Oral Fosamprenavir + Sodium Alginate for GERD

Inclusion Criteria: 1. Patient aged 18-65 selected as candidate for anti-reflux surgery by study providers. 2. Patient has received, and continued having GERD symptoms during, standard-labeled dose, daily, PPI therapy for a minimum of 8 weeks before the Screening Visit. 3. Patient has a diagnosis of GERD with endoscopy and/or pH-metry test within the past two years demonstrating 1 or more of the following: 1. Erosive esophagitis (Grade A or greater based on the Los Angeles classification of esophagitis; Appendix 3) 2. Evidence of pathological acid reflux (pH \< 4 for ≥ 4-6% off therapy or ≥ 1-4% on therapy) during a 24-hour time interval of pH testing 4. Patient reports heartburn severity (HS, Item #1 on mRESQ-eD) ≥ 3 (moderate) on at least 2 days and has an average HS of ≥ 2 (mild) during the last 7 days of the Pretreatment Period before Randomization. Exclusion Criteria: 1. Patient is suspected of having, functional upper gastrointestinal disorders such as functional dyspepsia or functional heartburn diagnosed by the Rome IV criteria; Appendix 4. 2. Patient has endoscopically confirmed eosinophilic esophagitis (EE).